Sangamo Therapeutics (SGMO)

$0.57 +0.03 (6.15%)
Market Cap 169.11M
Revenue (ttm) 57.80M
Net Income (ttm) -97.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -169.45%
Debt to Equity Ratio 0.00
Volume 5,737,400
Avg Vol 6,202,928
Day's Range N/A - N/A
Shares Out 301.71M
Stochastic %K 82%
Beta 1.18
Analysts Strong Sell
Price Target $4.10

Company Profile

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 970 6000
Address:
501 Canal Blvd, Richmond, United States
MCoronado
MCoronado Aug. 22 at 4:13 AM
$SGMO does Simple Steve post here too?
0 · Reply
TwoThirdsProbablyDown
TwoThirdsProbablyDown Aug. 22 at 12:53 AM
$SGMO This stock is almost as manic as our emotions on this SP rollercoaster.
1 · Reply
HeavyDtwitter
HeavyDtwitter Aug. 21 at 11:41 PM
$SGMO APUS Low float 80% institutions ‼️‼️
0 · Reply
Swamp_Yankee
Swamp_Yankee Aug. 21 at 10:38 PM
$SGMO i think Sandy is trying to avoid Erin. Comin in hot.
0 · Reply
Swamp_Yankee
Swamp_Yankee Aug. 21 at 10:26 PM
$SGMO Green on a relatively red day. Hmmmmmm.
0 · Reply
JackBogleG
JackBogleG Aug. 21 at 9:14 PM
$SGMO #SGMO Near-term target price $1-$1.8
1 · Reply
JackBogleG
JackBogleG Aug. 21 at 9:05 PM
$SGMO has numerous key catalysts: #SGMO near-term price target $1-$1.80 ✅ Phase II data for Fabry disease ✅ Countdown to Biologics License Application (BLA) submission ✅ Ongoing negotiations for potential commercialization collaborations HC Wainwright maintains a strong bullish outlook and has ample cash reserves to support R&D.
0 · Reply
biotech
biotech Aug. 21 at 8:34 PM
$SGMO Cantor KOL sees market interest in #Fabry Gene Therapy ... wonder how $FDMT Fabry program made it on the recent Cantor Slide ... this is Bullshit ... FDMT no longer developing this and cantor already said having a hard time seeing any effect of the program ... $SGMO Fabry LAST and ONLY one
3 · Reply
dbadoo
dbadoo Aug. 21 at 8:06 PM
$SGMO unless we can break .60 they’re just going to keep pushing it back down
0 · Reply
JimiJoJeeter
JimiJoJeeter Aug. 21 at 8:01 PM
$SGMO I'd expect a bigger jump in price and volume if news was pending. I'm sorry, but i'm not seeing it. But, smart money is accumulating!
1 · Reply
Latest News on SGMO
Sangamo Therapeutics, Inc. (SGMO) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 2:53 PM EDT - 13 days ago

Sangamo Therapeutics, Inc. (SGMO) Q2 2025 Earnings Call Transcript

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results

Aug 7, 2025, 4:01 PM EDT - 14 days ago

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results

Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call

Jul 31, 2025, 4:05 PM EDT - 21 days ago

Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease

Jun 24, 2025, 8:05 AM EDT - 2 months ago

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease

Sangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call Transcript

May 12, 2025, 9:06 PM EDT - 3 months ago

Sangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call Transcript

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results

May 12, 2025, 6:26 PM EDT - 3 months ago

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results

Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering

May 12, 2025, 6:23 PM EDT - 3 months ago

Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering

Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day

May 12, 2025, 4:00 PM EDT - 3 months ago

Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day

Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

May 6, 2025, 4:35 PM EDT - 3 months ago

Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease

May 6, 2025, 8:30 AM EDT - 3 months ago

Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease

Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Apr 28, 2025, 4:31 PM EDT - 4 months ago

Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal

Apr 4, 2025, 2:57 PM EDT - 4 months ago

Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

Apr 3, 2025, 4:01 PM EDT - 5 months ago

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

Sangamo Therapeutics, Inc. (SGMO) Q4 2024 Earnings Call Transcript

Mar 17, 2025, 6:29 PM EDT - 5 months ago

Sangamo Therapeutics, Inc. (SGMO) Q4 2024 Earnings Call Transcript

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Mar 17, 2025, 4:01 PM EDT - 5 months ago

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference

Mar 6, 2025, 4:05 PM EST - 6 months ago

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile

Feb 6, 2025, 8:05 AM EST - 7 months ago

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sangamo Therapeutics, Inc. (SGMO) And Encourages Shareholders to Reach Out

Jan 15, 2025, 10:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sangamo Therapeutics, Inc. (SGMO) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Shareholders to Learn More About the Investigation

Jan 14, 2025, 10:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Shareholders to Learn More About the Investigation

Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jan 13, 2025, 10:00 AM EST - 7 months ago

Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Shareholders to Inquire about Securities Investigation

Jan 12, 2025, 10:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Shareholders to Inquire about Securities Investigation

Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jan 10, 2025, 10:00 AM EST - 7 months ago

Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sangamo Therapeutics, Inc. (SGMO) And Encourages Investors to Connect

Jan 9, 2025, 10:00 AM EST - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sangamo Therapeutics, Inc. (SGMO) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Stockholders to Inquire about Securities Investigation

Jan 8, 2025, 10:00 AM EST - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Investors to Learn More About the Investigation

Jan 7, 2025, 10:00 AM EST - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Investors to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sangamo Therapeutics, Inc. (SGMO) And Encourages Stockholders to Connect

Jan 6, 2025, 10:00 AM EST - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sangamo Therapeutics, Inc. (SGMO) And Encourages Stockholders to Connect

Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jan 5, 2025, 10:00 AM EST - 8 months ago

Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Stockholders to Learn More About the Investigation

Jan 3, 2025, 10:00 AM EST - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Stockholders to Learn More About the Investigation

Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

Jan 2, 2025, 6:00 PM EST - 8 months ago

Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

Sangamo Therapeutics, Inc. (SGMO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Jan 2, 2025, 4:00 PM EST - 8 months ago

Sangamo Therapeutics, Inc. (SGMO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Jan 2, 2025, 3:05 PM EST - 8 months ago

Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Investors to Inquire about Securities Investigation

Jan 2, 2025, 10:15 AM EST - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Investors to Inquire about Securities Investigation

Crude Oil Rises 1%; Sangamo Therapeutics Shares Plummet

Dec 31, 2024, 12:01 PM EST - 8 months ago

Crude Oil Rises 1%; Sangamo Therapeutics Shares Plummet

Sangamo Therapeutics' stock falls the most in 16 years after Pfizer ends Hemophilia pact

Dec 31, 2024, 11:22 AM EST - 8 months ago

Sangamo Therapeutics' stock falls the most in 16 years after Pfizer ends Hemophilia pact

PFE

Sangamo Therapeutics Stock Crashes as Pfizer Ends Hemophilia Drug Pact

Dec 31, 2024, 11:20 AM EST - 8 months ago

Sangamo Therapeutics Stock Crashes as Pfizer Ends Hemophilia Drug Pact

MCoronado
MCoronado Aug. 22 at 4:13 AM
$SGMO does Simple Steve post here too?
0 · Reply
TwoThirdsProbablyDown
TwoThirdsProbablyDown Aug. 22 at 12:53 AM
$SGMO This stock is almost as manic as our emotions on this SP rollercoaster.
1 · Reply
HeavyDtwitter
HeavyDtwitter Aug. 21 at 11:41 PM
$SGMO APUS Low float 80% institutions ‼️‼️
0 · Reply
Swamp_Yankee
Swamp_Yankee Aug. 21 at 10:38 PM
$SGMO i think Sandy is trying to avoid Erin. Comin in hot.
0 · Reply
Swamp_Yankee
Swamp_Yankee Aug. 21 at 10:26 PM
$SGMO Green on a relatively red day. Hmmmmmm.
0 · Reply
JackBogleG
JackBogleG Aug. 21 at 9:14 PM
$SGMO #SGMO Near-term target price $1-$1.8
1 · Reply
JackBogleG
JackBogleG Aug. 21 at 9:05 PM
$SGMO has numerous key catalysts: #SGMO near-term price target $1-$1.80 ✅ Phase II data for Fabry disease ✅ Countdown to Biologics License Application (BLA) submission ✅ Ongoing negotiations for potential commercialization collaborations HC Wainwright maintains a strong bullish outlook and has ample cash reserves to support R&D.
0 · Reply
biotech
biotech Aug. 21 at 8:34 PM
$SGMO Cantor KOL sees market interest in #Fabry Gene Therapy ... wonder how $FDMT Fabry program made it on the recent Cantor Slide ... this is Bullshit ... FDMT no longer developing this and cantor already said having a hard time seeing any effect of the program ... $SGMO Fabry LAST and ONLY one
3 · Reply
dbadoo
dbadoo Aug. 21 at 8:06 PM
$SGMO unless we can break .60 they’re just going to keep pushing it back down
0 · Reply
JimiJoJeeter
JimiJoJeeter Aug. 21 at 8:01 PM
$SGMO I'd expect a bigger jump in price and volume if news was pending. I'm sorry, but i'm not seeing it. But, smart money is accumulating!
1 · Reply
Newtimmy
Newtimmy Aug. 21 at 7:52 PM
$SGMO if this thing runs to.62+ these last 7 mins, just wait for the PR
0 · Reply
Newtimmy
Newtimmy Aug. 21 at 7:50 PM
$SGMO sure seems something is got out
0 · Reply
Danielsss
Danielsss Aug. 21 at 7:39 PM
$SGMO something brewing
0 · Reply
TangoToEvora
TangoToEvora Aug. 21 at 7:37 PM
$SGMO Small P&D?
0 · Reply
JimiJoJeeter
JimiJoJeeter Aug. 21 at 7:34 PM
$SGMO WTF.....
0 · Reply
Andi422
Andi422 Aug. 21 at 7:29 PM
$SGMO something seems to be in the air
0 · Reply
Newtimmy
Newtimmy Aug. 21 at 7:18 PM
$SGMO Looking
0 · Reply
SilentSniper
SilentSniper Aug. 21 at 7:14 PM
$SGMO
0 · Reply
PurpleTurkey
PurpleTurkey Aug. 21 at 7:10 PM
$SGMO
2 · Reply
mystic_13
mystic_13 Aug. 21 at 7:09 PM
$SGMO Positive bullish momentum building up.
0 · Reply
Florent666
Florent666 Aug. 21 at 7:06 PM
$SGMO I love you 🥹
0 · Reply
Flyingalbo
Flyingalbo Aug. 21 at 6:56 PM
$SGMO it’s creeping up
1 · Reply